- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04659863
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia (ORION-13)
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 4W2
- Novartis Investigative Site
-
-
-
-
-
Bron Cedex, France, 69677
- Novartis Investigative Site
-
-
-
-
-
Athens, Greece, 18547
- Metropolitan Hospital
-
-
GR
-
Ioannina, GR, Greece, 455 00
- University General Hospital of Ioannina
-
-
-
-
-
Ashrafieh, Lebanon, 166830
- Hotel Dieu de France Hospital
-
Beirut, Lebanon, 1107 2020
- American University of Beirut Medical Center
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Novartis Investigative Site
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Novartis Investigative Site
-
-
-
-
-
Izmir, Turkey, 35040
- Novartis Investigative Site
-
-
TUR
-
Istanbul, TUR, Turkey, 34098
- Novartis Investigative Site
-
-
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Excel Medical Clinical Trials LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Homozygous Familial Hypercholesterolemia (HoFH) diagnosed by genetic confirmation
- Fasting LDL-C >130 mg/dL (3.4 mmol/L) at screening
- On maximally tolerated dose of statin (investigator's discretion) with or without other lipid-lowering therapy; stable for ≥ 30 days before screening
- Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 at screening
Exclusion Criteria:
- Documented evidence of a null (negative) mutation in both LDLR alleles
- Heterozygous familial hypercholesterolemia (HeFH)
- Active liver disease
- Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome
- Major adverse cardiovascular events within 1 month prior to randomization
- Previous treatment with monoclonal antibodies directed towards PCSK9 (within 90 days of screening)
- Treatment with mipomersen or lomitapide (within 5 months of screening)
- Recent and/or planned use of other investigational medicinal products or devices
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inclisiran
Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
|
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
Other Names:
|
Placebo Comparator: Placebo
Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
|
Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330
Time Frame: Baseline and Day 330
|
Evaluate the effect of inclisiran compared to placebo on reducing LDL-C [percent change] at Day 330 (Year 1)
|
Baseline and Day 330
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-adjusted percent change in LDL-C from baseline after Day 90 and up to Day 330
Time Frame: Baseline, after Day 90 up to Day 330
|
Evaluate the effect of inclisiran compared to placebo on reducing LDL-C [time-adjusted percent change] over Year 1
|
Baseline, after Day 90 up to Day 330
|
% change and absolute change in LDL-C from baseline up to Day 720
Time Frame: Baseline, up to Day 720
|
Evaluate the effect of inclisiran compared to placebo (for Year 1) and long-term (up to Day 720), on lowering LDL-C over time
|
Baseline, up to Day 720
|
% change and absolute change in other lipoprotein and lipid parameters from baseline up to Day 720
Time Frame: Baselne, up to Day 720
|
Evaluate the effect of inclisiran compared to placebo (up to Day 330) and long-term (up to Day 720), on lowering apolipoprotein B (Apo B), lipoprotein (a) [Lp(a)], non-high density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein A1 (Apo A1) over time
|
Baselne, up to Day 720
|
% change and absolute change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline up to Day 720
Time Frame: Baseline, up to Day 720
|
Evaluate the effect of inclisiran compared to placebo (up to Day 330) and long-term (up to Day 720), on lowering PCSK9 over time
|
Baseline, up to Day 720
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publications and helpful links
General Publications
- Reijman MD, Schweizer A, Peterson ALH, Bruckert E, Stratz C, Defesche JC, Hegele RA, Wiegman A. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022 Jul 20;29(9):1361-1368. doi: 10.1093/eurjpc/zwac025.
- Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CKJX839C12302
- 2020-002755-38 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Hypercholesterolemia - Homozygous
-
Novartis PharmaceuticalsRecruitingHeterozygous or Homozygous Familial HypercholesterolemiaNetherlands, Israel, Hungary, Italy, Germany, Spain, France, Norway, South Africa, Turkey, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, United States, Russian Federation, Taiwan
-
REGENXBIO Inc.National Heart, Lung, and Blood Institute (NHLBI)TerminatedHomozygous Familial Hypercholesterolemia (HoFH)United States, Canada, Italy, Netherlands
-
Institut Investigacio Sanitaria Pere VirgiliRecruitingFamilial Hypercholesterolemia | Familial Hypercholesterolemia - Homozygous | Familial Hypercholesterolemia - HeterozygousSpain
-
Novartis PharmaceuticalsCompletedElevated Cholesterol | Homozygous Familial Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia | ASCVDUnited States, Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
AmgenCompletedFamilial HypercholesterolemiaCanada, Italy, Norway, Belgium, United States, Turkey, Australia, Austria, South Africa, Poland, Switzerland, Spain, Portugal, Slovenia, Brazil, Russian Federation, Hungary, United Kingdom, Colombia, Czechia, Netherlands, Greece, Ma...
-
Daniel GaudetUltragenyx Pharmaceutical IncActive, not recruitingSafety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaCanada
-
Regeneron PharmaceuticalsCompletedHomozygous Familial HypercholesterolemiaUnited States, Netherlands, South Africa, Australia, Austria, Canada, Czechia, France, Greece, Italy, Japan, Ukraine
-
Nantes University HospitalCompletedStudy of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia (SAFIR)Homozygous Familial HypercholesterolemiaFrance
-
The Medicines CompanyCompletedHomozygous Familial HypercholesterolemiaUnited States, Netherlands, South Africa
Clinical Trials on Inclisiran
-
Novartis PharmaceuticalsActive, not recruitingPrimary Hypercholesterolemia or Mixed DyslipidemiaChina
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedElevated Cholesterol | Homozygous Familial Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia | ASCVDUnited States, Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
Federico II UniversityRecruiting
-
Novartis PharmaceuticalsRecruitingHypercholesterolaemia | Familial HypercholesterolaemiaJapan
-
Novartis PharmaceuticalsRecruitingMixed Dyslipidemia | Primary HypercholesterolemiaChina
-
The Medicines CompanyCompleted
-
Novartis PharmaceuticalsCompletedAtherosclerotic Cardiovascular DiseaseUnited States
-
Novartis PharmaceuticalsActive, not recruiting